what do patients with inflammatory bowel disease want for their clinical management?
N Westwood, SPL Travis - Alimentary pharmacology & …, 2008 - Wiley Online Library
Background The patient's perceptions of benefits and risks of treatment differ from those of
physicians, yet this topic is rarely explored in ulcerative colitis or Crohn's disease. Aim To …
physicians, yet this topic is rarely explored in ulcerative colitis or Crohn's disease. Aim To …
Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease
CA Siegel, CL Levy, TA MacKenzie… - Inflammatory bowel …, 2008 - academic.oup.com
Background For a patient to make informed, preference based decisions, they must be able
to balance the risks and benefits of treatment. The aim of this study was to determine …
to balance the risks and benefits of treatment. The aim of this study was to determine …
Serious events with infliximab in patients with inflammatory bowel disease: a 9-year cohort study in the Netherlands
HS de Vries, MGH van Oijen, DJ de Jong - Drug safety, 2008 - Springer
Background: The tumour necrosis factor-α inhibitor infliximab is incorporated in the treatment
guidelines for patients with inflammatory bowel disease (IBD). However, concerns about …
guidelines for patients with inflammatory bowel disease (IBD). However, concerns about …
Survey-design and analytical strategies for better healthcare stated-choice studies
FR Johnson, C Mansfield - The Patient: Patient-Centered Outcomes …, 2008 - Springer
Abstract Stated-choice (SC) surveys, such as conjoint analysis, present some interesting
problems for researchers that are not addressed in the traditional survey-development …
problems for researchers that are not addressed in the traditional survey-development …
Combination therapy of infliximab and azathioprine reduces disease progression in Crohn's disease
S Din, CJ Cochrane, CL Noble… - Inflammatory bowel …, 2008 - academic.oup.com
More than 15 years after the first case report demonstrating the use of infliximab in refractory
Crohn's disease (CD), 1 the optimum position of antitumor necrosis factor (TNF) therapy in …
Crohn's disease (CD), 1 the optimum position of antitumor necrosis factor (TNF) therapy in …
[PDF][PDF] Tratamiento con agentes anti-TNF en la enfermedad de Crohn:¿ qué fármaco debemos utilizar y cuándo?
F Gomollón, SG López - Acta Gastroenterológica Latinoamericana, 2008 - redalyc.org
La enfermedad de Crohn (EC) es, a menudo, de muy difícil tratamiento. Desde hace ya 10
años disponemos de los agentes" biológicos" para su tratamiento. Aunque hay muchos …
años disponemos de los agentes" biológicos" para su tratamiento. Aunque hay muchos …
Communicating the safety of inflammatory bowel disease therapies: risk versus reality
CA Siegel - Gastroenterology Nursing, 2008 - journals.lww.com
Patients are naturally concerned about these risks, but the reality is that they are very small
considering the hundreds of thousands of doses of anti-TNF therapy given to date. It can …
considering the hundreds of thousands of doses of anti-TNF therapy given to date. It can …
[PDF][PDF] x REVISIÓN
F Gomollón, SG López - Acta Gastroenterol Latinoam, 2008 - actagastro.org
La enfermedad de Crohn (EC) es, a menudo, de muy difícil tratamiento. Desde hace ya 10
años disponemos de los agentes" biológicos" para su tratamiento. Aunque hay muchos …
años disponemos de los agentes" biológicos" para su tratamiento. Aunque hay muchos …
[PDF][PDF] Maladies inflammatoires
C Felley, C Mottet, MH Maillard, J Hess, J Delarive… - Rev Med Suisse, 2008 - revmed.ch
Revue Médicale Suisse–www. revmed. ch–23 janvier 2008 0 rapie par infliximab donnée à
intervalles réguliers. En l'absence de bénéfice évident et au vu du risque oncologique de …
intervalles réguliers. En l'absence de bénéfice évident et au vu du risque oncologique de …